A critical role for the programmed death ligand 1 in fetomaternal tolerance

被引:336
|
作者
Guleria, I [1 ]
Khosroshahi, A
Ansari, MJ
Habicht, A
Azuma, M
Yagita, H
Noelle, RJ
Sayegh, MH
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA
[4] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo 1138549, Japan
[5] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan
[6] Dartmouth Coll, Hanover, NH 03755 USA
[7] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA
[8] Med Coll Georgia, Dept Med, Inst Mol Med & Genet, Program Mol Immunol, Augusta, GA 30912 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2005年 / 202卷 / 02期
关键词
D O I
10.1084/jem.20050019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fetal survival during gestation implies that tolerance mechanisms suppress the maternal immune response to paternally inherited alloantigens. Here we show that the inhibitory T cell costimulatory molecule, programmed death ligand 1 (PDL1), has an important role in conferring fetomaternal tolerance in an allogeneic pregnancy model. Blockade of PDL1 signaling during murine pregnancy resulted in increased rejection rates of allogeneic concepti but not syngeneic concepti. Fetal rejection was T cell - but not B cell - dependent because PDL1-specific antibody treatment caused fetal rejection in B cell - deficient but not in RAG-1-deficient females. Blockade of PDL1 also resulted in a significant increase in the frequency of IFN-gamma-producing lymphocytes in response to alloantigen in an ELISPOT assay and higher IFN-gamma levels in placental homogenates by ELISA. Finally, PDL1-deficient females exhibited decreased allogeneic fetal survival rates as compared with littermate and heterozygote controls and showed evidence of expansion of T helper type 1 immune responses in vivo. These results provide the first evidence that PDL1 is involved in fetomaternal tolerance.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 50 条
  • [41] Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
    Jiang, Yao
    Hong, Kai
    Zhao, Yingchao
    Xu, Kai
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] The Role of Programmed Cell Death 1/Programmed Death Ligand 1 (PD-1/PD-L1) Axis in Sepsis-Induced Apoptosis
    Coman, Oana
    Grigorescu, Bianca-Liana
    Hutanu, Adina
    Bacarea, Anca
    Vasiesiu, Anca Meda
    Fodor, Raluca Stefania
    Stoica, Florin
    Azamfirei, Leonard
    MEDICINA-LITHUANIA, 2024, 60 (07):
  • [43] Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression
    Chen, Man-Chin
    Pangilinan, Christian Ronquillo
    Lee, Che-Hsin
    CANCERS, 2020, 12 (01)
  • [44] Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    Bomze, David
    Azoulay, Daniel
    Meirson, Tomer
    JAMA ONCOLOGY, 2020, 6 (07) : 1114 - 1115
  • [45] Programmed death ligand 1 signals in cancer cells
    Anand V. R. Kornepati
    Ratna K. Vadlamudi
    Tyler J. Curiel
    Nature Reviews Cancer, 2022, 22 : 174 - 189
  • [46] Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade
    Ganbaatar, Otgontuya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nojima, Yutaro
    Maekawa, Naoya
    Ichikawa, Yoshiki
    Kobayashi, Atsushi
    Shibahara, Tomoyuki
    Yanagawa, Yojiro
    Higuchi, Hidetoshi
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1573 - 1583
  • [47] OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A386 - A387
  • [48] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
    Liu, Xiaojun
    Yang, Zhongxia
    Latchoumanin, Olivier
    Qiao, Liang
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860
  • [49] Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
    Fang, Xiao-Na
    Fu, Li-Wu
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (02) : 141 - 151
  • [50] Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer
    Miyashita, Hirotaka
    Mikami, Takahisa
    Satoi, Sera
    Cruz, Christina
    Galsky, Matthew D.
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 291 - 298